[Show abstract][Hide abstract] ABSTRACT: To investigate choroidal thickness (CT) in healthy Korean subjects measured by enhanced depth imaging optical coherence tomography and its association with age, axial length, and refractive error.
Choroidal scans using enhanced depth imaging optical coherence tomography in each eye of 286 healthy eyes were obtained at the macula. Choroidal thickness was measured at the fovea. Two separate line scans were obtained (one horizontal and one vertical).
The mean (±SD) age was 40.18 (±17.89) years (range, 13 to 75 years). The mean (±SD) subfoveal CT was 307.26 (±95.18) μm. Multivariable linear regression suggested that age and refractive error were the most significant factors associated with subfoveal CT (all p < 0.0001) with an adjusted R = 0.181. In subjects younger than 60 years, refractive error or axial length and age retained statistically significant correlation with subfoveal CT, whereas such a relationship was lost in subjects older than 60 years.
The mean subfoveal CT measurement showed the most significant positive correlation with refractive error and the most significant negative correlation with age. For patients younger than 60 years, there was a significant correlation of subfoveal CT with age and refractive error or axial length, whereas such significant association was not observed in subjects older than 60 years.
Optometry and vision science: official publication of the American Academy of Optometry 04/2014; · 1.53 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: This case describes the reversal of early central retinal vein occlusion (CRVO) with disc swelling after intravitreal dexamethasone implant (Ozurdex) injection. A 44-year-old female presented with sudden-onset intermittent blurred vision in her left eye. Fundus examination revealed multiple retinal hemorrhages without macular edema (ME). Two weeks later, an increased number of retinal hemorrhages with severe disc swelling were noted with still no sign of ME. An intravitreal dexamethasone implant was injected. Five days later, there were improvements in disc swelling and retinal hemorrhage. One month later, her subjective visual symptoms were completely improved, and fundus examination revealed marked improvement along with almost complete resolution of disc swelling. Intravitreal dexamethasone implant injection may potentially change the natural course of CRVO progression and its various subsequent complications.
Korean Journal of Ophthalmology 04/2014; 28(2):192-3.
[Show abstract][Hide abstract] ABSTRACT: To evaluate the characteristics of rhegmatogenous retinal detachment (RD) in patients with previous laser in-situ keratomileusis (LASIK) and compared them to RD in patients with previous laser assisted sub-epithelial keratomileusis (LASEK) and myopic patients with no previous refractive surgery.
Retrospective, comparative case series METHODS: Among 106 eyes of 106 patients, RD patients with previous refractive surgery included 21 eyes with LASIK and 13 eyes with LASEK. 72 myopic patients with refractive errors of -3.0 diopters or less were grouped as the R (-) group. Characteristics of RD included distribution of RD and associated retinal breaks, location and number of retinal breaks, presence of lattice degeneration, and axial lengths.
The mean interval between refractive surgery and the onset of rhegmatogenous RD was 63.7±43.5 months, occurring across a broad spectrum of time interval. There were no significant differences among LASIK group, LASEK group, and R (-) group in axial length (26.8 mm vs. 26.4 mm vs. 26.9 mm, respectively), mean number of retinal holes/tears, (2.1/1.5, 0.9/1.4, 1.5/1.6, respectively) and the presence of lattice degeneration(52.4%vs. 46.2% vs. 43.1%, respectively). Distribution of RD and associated retinal breaks were also not significant different, as retinal holes and tears were more prevalent in the temporal quadrants, and inferotemporal quadrants was the most commonly detached area in both LASEK/LASIK group and R (-) group.
Myopia is a well-known risk factor for rhegmatogenous RD and may contribute more to the development of RD in myopic patients after refractive surgery, rather than refractive surgery itself.
American Journal of Ophthalmology 12/2013; · 4.02 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: To investigate the prevalence of polypoidal choroidal vasculopathy (PCV) in patients with myopic choroidal neovascularization (CNV) using indocyanine green angiography (ICGA).
Retrospective cross-sectional study.
A total of 297 eyes (255 patients) who presented with treatment-naive myopic CNV between January 2005 and December 2011 at Yonsei University Medical Center in Seoul, South Korea, were reviewed. Fluorescein angiography (FA) images obtained from the patients were analyzed to detect CNV presence and classify disease type. ICGA images were reviewed to detect polypoidal lesions. The main outcome measure was the prevalence of polypoidal lesions in patients with myopic CNV.
All 297 eyes with myopic CNV were type 2 CNV, and mean age at diagnosis was 47.32 ± 14.69 years. The mean refractive error was -11.95 ± 5.88 diopters, and the mean axial length was 29.39 ± 2.02 mm in the affected eyes. Among the myopic CNV eyes, 141 eyes (118 patients) were older than 50 years of age (mean 60.48 ± 7.34 years). No eyes with myopic CNV showed polypoidal lesions on ICGA at initial presentation. After treatments for myopic CNV, 243 eyes (206 patients) completed at least 12 months of follow-up, and 86 eyes (35.4%) showed at least one recurrence of CNV during follow-up. The follow-up imaging studies, FA, and ICGA, showed no polypoidal lesions associated with recurred myopic CNV.
ICGA analysis demonstrated no polypoidal component in myopic eyes with CNV.
American Journal of Ophthalmology 12/2013; · 4.02 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: To evaluate the long-term visual outcome after combination therapy of photodynamic therapy (PDT) with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy (PCV).
Retrospective, observational study.
The medical records of 34 eyes (34 patients) with naive PCV who were treated with combination therapy were analyzed. All patients completed at least 3 years of follow-up. All clinical data, including age, best-corrected visual acuity (BCVA, logMAR; logarithm of the minimum angle resolution), imaging data of fluorescein angiography, indocyanine green angiography, and optical coherence tomography, were investigated.
During a mean follow-up period of 46.82 ± 5.22 months, a mean of 1.44 ± 0.71 times of PDT and 9.18 ± 6.61 intravitreal bevacizumab injections were performed. During follow-up, 21 eyes (61.8%) showed at least one recurrence. Mean BCVA was 0.59 ± 0.35 logMAR (20/77 Snellen equivalent) at baseline, and 0.39 ± 0.34 logMAR (20/49 Snellen equivalent) at 3 years (P=.004). At 3 years, 14 patients (41.2%) gained 0.3 logMAR or more BCVA, and 4 patients (11.8%) lost 0.3 logMAR or more BCVA than baseline. Baseline polyp size (B=.551; P=.005) and location of polyps (B= -.400; P=.033) were significantly correlated with long-term visual outcome after combination therapy for PCV.
Combination therapy of PDT with intravitreal bevacizumab injections showed favorable visual outcomes, and significant visual improvement was maintained in PCV patients. A total of 88.2% of patients avoided visual loss at 3 years after treatments. Largest polyp size at baseline and location of polypoidal lesions were prognostic factors for long-term visual outcomes in these patients.
American Journal of Ophthalmology 11/2013; · 4.02 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Purpose: To evaluate the change in choroidal thickness (CT) between active and quiescent phases of Behcet's posterior uveitis and compare this to the normal population using enhanced depth imaging optical coherence tomography (EDI-OCT). Methods: Thirty eyes from 30 patients with Behcet's posterior uveitis (mean age, 47.03 ± 11.01 years) were retrospectively enrolled in the study. Their subfoveal CT was measured using EDI-OCT in the active and quiescent phases of Behcet's uveitis, and compared with the age, sex, and spherical equivalent-matched normal population. Changes in retinal vascular leakage on fluorescein angiography (FA) were correlated with the changes in CT. Results: Mean subfoveal CT in the acute phase of Behcet uveitis was significantly greater than that in the quiescent phase (398.77 ± 155.59 μm vs 356.72 ± 141.09 μm; p=0.004). CT in the quiescent phase was also significantly greater than that of the normal population (259.96 ± 65.16 μm; p<0.0001). There was a statistically significant association between the change in subfoveal CT and the change in vascular leakage revealed by FA. (ρ = 0.381, p=0.046). Subfoveal CT in the uninvolved fellow eyes of patients with unilateral Behcet's uveitis was also evaluated and it was significantly greater than that of the normal population. (n=13 eyes; p=0.001) Conclusions: This study found choroidal thickening during the active phase of Behcet's posterior uveitis. CT during the quiescent phase was also significantly greater than in normal eyes. The degree of reduction in choroidal thickening was significantly correlated with improvement in retinal vascular leakage as revealed by FA.
[Show abstract][Hide abstract] ABSTRACT: To evaluate long-term visual outcome and investigate the prognostic factors after anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV).
Analyses were done among 36 eyes (36 patients) with naïve PCV that were treated with intravitreal ranibizumab injections and completed at least 3-year follow-up. All clinical data, including baseline characteristics; imaging data from fluorescein angiography, indocyanine green angiography, and optical coherence tomography; presence of recurrence; and best-corrected visual acuity (BCVA) were investigated.
During mean follow-up of 42.58 ± 12.59 months, mean numbers of anti-VEGF injection were 11.45 ± 7.81. Twenty-four eyes (66.7%) showed at least 1 recurrence during follow-up. Mean baseline BCVA was 0.68 ± 0.43 logMAR (20/95 Snellen equivalent), and 0.78 ± 0.53 logMAR (20/120 Snellen equivalent) at 36 months (P = .307). Mean BCVA was significantly improved at 1 month (P = .018), and improvement was maintained until 12 months (P = .044), then deteriorated. Among baseline characteristics, greatest lesion diameter (B = 0.219, P = .001) and pigment epithelial detachment (B = 0.362, P = .025) were significantly correlated with long-term visual outcome. Recurrence during follow-up (B = 0.371, P = .024) was also significantly correlated with long-term visual outcome.
Significant visual improvement by anti-VEGF therapy was maintained during the first year of initial treatment; however, vision then deteriorated during long-term follow-up. Smaller lesion size, absence of pigment epithelial detachment at baseline, and no recurrence during follow-up were significantly correlated with better long-term visual outcome.
American Journal of Ophthalmology 07/2013; · 4.02 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: PURPOSE:: To investigate factors associated with long-term recurrence of myopic choroidal neovascularization (CNV) after treatment with photodynamic therapy (PDT) and/or intravitreal antivascular endothelial growth factor injections. METHODS:: Seventy-six eyes with myopic CNV completed at least a 48-month follow-up after treatments. The baseline characteristics of the eyes were compared, including age, gender, refractive errors, axial lengths, location of CNV, lacquer cracks, chorioretinal atrophy, dark rim, great linear dimension, and prior PDT. RESULTS:: During mean follow-up of 71.21 ± 26.43 months, 35 eyes (46.1%) experienced at least 1 recurrence. Mean interval between initial treatment and first recurrence was 24.15 ± 18.10 months. Presence of lacquer crack (P = 0.022, χ test), absence of dark rim (P = 0.031, χ test), and prior PDT (P = 0.041, χ test) were significantly different between the eyes with and without recurrence. Among baseline characteristics, presence of lacquer crack (β = 1.272, P = 0.012) prior PDT (β = 1.607, P = 0.027), and absence of dark rim (β = -0.758, P = 0.020) were significantly associated with the recurrence of myopic CNV after treatment by multiple logistic regression. CONCLUSION:: Long-term follow-up revealed recurrence of myopic CNV in 46.1% of the patients after treatment. Presence of lacquer cracks, prior PDT, and absence of dark rim were risk factors for recurrence of myopic CNV.
[Show abstract][Hide abstract] ABSTRACT: A 5-year-old girl was diagnosed with neurofibromatosis type 2 (NF-2) due to multiple neurofibromas, cafe-au-lait spots, and schwannomas of the brain. During ophthalmologic evaluation, a posterior subcapsular cataract and a gray-green colored subretinal lesion were found in right eye. Fluorescein angiography (FA) revealed a combined hamartoma of the retina and retinal pigment epithelium (CHRRPE). At age 9, she underwent cataract surgery. At this time FA and spectral-domain optical coherence tomography (SD-OCT) were taken. The SD-OCT showed an elevated hyperreflective mass in the retina with prominent attenuation of the inner and outer retina, but minimal attenuation in the photoreceptor layers. The underlying retina appeared to be disorganized and thick (791 µm). This is the first case report of SD-OCT imaging of a CHRRPE associated with NF-2 in a pediatric patient. By using SD-OCT in this patient, we could obtain detailed tumor characteristics, and SD-OCT may be helpful in the diagnosis and management of CHRRPE.
Korean Journal of Ophthalmology 02/2013; 27(1):68-71.
[Show abstract][Hide abstract] ABSTRACT: PURPOSE: To compare visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) injection or photodynamic therapy (PDT) for idiopathic choroidal neovascularization (CNV). DESIGN: Retrospective study. METHODS: Among 29 eyes (28 patients), 15 eyes (15 patients) received anti-VEGF therapy and 14 eyes (13 patients) received PDT. Best-corrected visual acuity (BCVA, logMAR [logarithm of minimal angle of resolution]) at baseline and 1, 3, 6, 12, and 24 months after initial treatment were compared. The eyes were classified by BCVA changes: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable. RESULTS: Mean BCVA was 0.56 ± 0.38 logMAR (20/72 in Snellen equivalent) in the PDT group and 0.44 ± 0.59 logMAR (20/55 in Snellen equivalent) in the anti-VEGF group at baseline (P = .104, Mann-Whitney U test). The anti-VEGF group showed significantly better mean BCVA at each follow-up visit when compared with that of PDT (P = .004 at 1 month, P = .002 at 3 months, P = .037 at 6 months, P = .031 at 12 months, and P = .049 at 24 months; Mann-Whitney U test, respectively). When compared with the baseline, mean BCVA at each follow-up visit was better in the anti-VEGF group (P = .196 at 1 month, P = .007 at 3 months, P = .046 at 6 months, P = .046 at 12 months, and P = .049 at 24 months; Wilcoxon signed rank test, respectively), whereas BCVA in the PDT group was not. At 24 months, all eyes (100.0%) treated with anti-VEGF showed stable or improved BCVA, whereas 3 eyes (21.3%) showed visual deterioration after PDT. CONCLUSIONS: Anti-VEGF therapy was superior to PDT for idiopathic CNV, and superior efficacy was sustained until 24 months.
American Journal of Ophthalmology 12/2012; · 4.02 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: PURPOSE: To evaluate the 5-year efficacy of photodynamic therapy (PDT) in patients with polypoidal choroidal vasculopathy (PCV). DESIGN: Retrospective study. METHODS: Forty-two eyes of 36 patients with PCV followed up for at least 60 months after PDT were reviewed. All eyes were primarily treated with PDT. Main outcome measure was best-corrected visual acuity (BCVA; logMAR [logarithm of minimal angle of resolution]) at baseline and at each follow-up visit. We also classified the eyes into 3 groups: improved (improvement ≥0.3 logMAR), decreased (deterioration ≥0.3 logMAR), and stable. RESULTS: During the mean follow-up duration, 73.64 ± 13.47 months, the mean number of PDT was 2.21 ± 1.62 treatments. Recurrence was noted in 33 eyes (78.6%) during follow-up. The mean baseline BCVA was 0.78 ± 0.48 logMAR (20/120 Snellen equivalent), and the final BCVA at 60 months was 0.67 ± 0.52 logMAR (20/93 Snellen equivalent) (P = .050, paired t test). On the final evaluation at 60 months, the mean BCVA was improved in 14 eyes (33.3%), stable in 23 eyes (54.7%), and decreased in 5 eyes (11.9%). CONCLUSION: At 60 months after initial PDT, 88.1% of PCV patients showed stable or improved BCVA after PDT. Despite a high recurrence rate, PDT remained effective for 5 years, and represents a good therapeutic approach to PCV.
American Journal of Ophthalmology 12/2012; · 4.02 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: PURPOSE: To investigate the correlation of choroidal thickness (CT) with ocular perfusion pressure (OPP) in young, healthy subjects using enhanced depth imaging optical coherence tomography (EDI-OCT). METHODS: A single horizontal section and a single vertical section of EDI-OCT scans in each eye of 69 young, healthy subjects were obtained at the macula. CT was measured at the fovea, and up to 3 mm, at intervals of 0.5 mm, away from the fovea in the superior, inferior, nasal, and temporal choroid. UNIVARIABLE AND MULTIVARIABLE ANALYSES WERE PERFORMED TO ASSESS THE ASSOCIATION OF CT WITH OPP WHILE AXIAL LENGTH (AL), REFRACTIVE ERROR (RE), GENDER AND/OR BODY MASS INDEX (BMI), WERE TAKEN INTO CONSIDERATION. RESULTS: Mean subfoveal CT was 307.03±91.27 μm. (The mean age, 22.3±3 years; the mean axial length, 25.35±1.14 mm; the mean refractive error, -3.89±2.02 diopters; the mean OPP, 44.18±5.49 mmHg). Multivariable regression analysis showed that in eyes with less than 6 diopters of myopia, subfoveal CT (325.92±88.46 μm) changed most significantly in association with RE and mean OPP (β=25.941, p<0.001; β=-3.551, p=0.042, respectively; adjusted R2=0.249). In subjects with myopia of more than 6 diopters, subfoveal CT (225.17±49.37 μm) was significantly thinner (p<0.0001), and a significant correlation with OPP was not observed (p>0.05). CONCLUSIONS: In vivo subfoveal CT as measured by EDI-OCT was significantly associated with OPP in young, healthy subjects when adjusted for RE, suggesting that subfoveal CT may be indirectly indicative of subfoveal ocular perfusion status. This association was not observed in subjects with high myopia.
[Show abstract][Hide abstract] ABSTRACT: BACKGROUND: To evaluate the baseline spectral-domain optical coherence tomography (SD-OCT) characteristics of macular edema (ME) due to branch retinal vein occlusion (BRVO) for visual outcome after intravitreal bevacizumab injection. METHODS: Fifty-nine patients treated in one eye with intravitreal bevacizumab for ME due to BRVO were retrospectively reviewed. Stepwise multiple regression analysis was used to evaluate the relative contribution of several variables, including SD-OCT characteristics such as photoreceptor inner segment/outer segment (IS/OS) integrity and external limiting membrane (ELM status), baseline best-corrected visual acuity (BCVA), and baseline central retinal thickness (CRT) with final visual outcome. RESULTS: Thirty-one patients (52.5 %) had disrupted photoreceptor IS/OS integrity. The mean BCVA improved significantly from 0.50 logMAR (20/63 Snellen equivalent) to 0.10 logMAR (20/25 Snellen equivalent) in the intact photoreceptor group (p = 0.000, paired t-test). However, the mean BCVA was improved in the disrupted photoreceptor group, from 1.10 logMAR (20/252 Snellen equivalent) to 0.94 logMAR (20/174 Snellen equivalent), which was not statistically significant (p = 0.177, paired t-test). ELM was disrupted in 23 patients (39.0 %). The mean BCVA improved significantly from 0.63 logMAR (20/85 Snellen equivalent) to 0.26 logMAR (20/36 Snellen equivalent) in the intact ELM group (p = 0.000, paired t-test), however, not significantly improved in the disrupted ELM group, from 1.09 logMAR (20/246 Snellen equivalent) to 1.01 logMAR (20/205 Snellen equivalent) (p = 0.563, paired t-test). The strongest individual predictor of final BCVA among patients with ME due to BRVO was the integrity of photoreceptor IS/OS layer on SD OCT (r (2) = 0.514, p = 0.000, stepwise multiple regression), but the most efficient model was the combination of the photoreceptor IS/OS integrity, ELM status, and baseline BCVA (r (2) = 0.671, p = 0.000, stepwise multiple regression). The strongest predictor of final BCVA was the status of photoreceptor IS/OS integrity (β = 0.532, p = 0.000, stepwise multiple regression), followed by ELM status (β = 0.325, p = 0.006, stepwise multiple regression), and the baseline BCVA (β = 0.238, p = 0.013, stepwise multiple regression). CONCLUSION: Our results suggest that baseline SD-OCT characteristics, the status of photoreceptor IS/OS and ELM can be helpful in predicting the final visual outcome after intravitreal bevacizumab injection in these patients.
Albrecht von Graæes Archiv für Ophthalmologie 06/2012; · 1.93 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Purpose: To evaluate the association between the macular structure on spectral-domain optical coherence tomography (SD-CT) and visual outcome after vitrectomy for lamellar macular hole (LMH). Methods: Best-corrected visual acuity (VA) and SD-OCT images of the macula were assessed before and after surgery in 30 eyes of 30 patients with a LMH. Preoperative VA and SD-OCT features were investigated as predictors of surgical outcome. Results: Mean patient age was 65 years with female predominance (77%). Visual acuity improved in 19 eyes (63%) with an overall mean improvement of 1 Snellen line (from 20/65 to 20/50; p = 0.002) at a mean of 18 months after vitrectomy. Subgroup analysis showed that statistically significant visual benefit was only observed in patients with an intact photoreceptor inner segment/outer segment (IS/OS) junction (p = 0.003), with foveal thickness bigger than 100 μm (p = 0.004) and with initial VA better than 20/100 (p = 0.003). The most efficient model to predict final VA was the combination of preoperative VA and the presence or absence of IS/OS disruption (r(2 ) =( ) 0.77, p < 0.001). Conclusions: Poor initial VA, the presence of a disrupted IS/OS junction or a thin fovea on preoperative SD-OCT predicted poor vision outcome after LMH surgery.
[Show abstract][Hide abstract] ABSTRACT: The aim of this study was to evaluate the prognostic factors of visual outcome after intravitreal anti-vascular endothelial growth factor injection in patients with myopic choroidal neovascularization (CNV).
Forty eyes of 40 consecutive patients with myopic CNV who had received intravitreal ranibizumab or bevacizumab injections were retrospectively reviewed. Baseline visual acuity, presence of lacquer crack, dark rim, peripapillary choroidal atrophy size, and location of myopic CNV were evaluated using fluorescein angiography and indocyanine green angiography.
The logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) at 12 months after treatment was 0.23 ± 0.28, and there was a significant improvement compared with the baseline BCVA (P = 0.001). After multiple linear regression analysis, baseline BCVA, presence of lacquer crack extending the fovea, and peripapillary choroidal atrophy size were the factors that significantly correlated with BCVA at 12 months (P = 0.001, P = 0.04, and P = 0.04). For mean change in BCVA over 12 months, there were also significant correlations with baseline BCVA, lacquer crack extension to the fovea, and peripapillary choroidal atrophy size (P = 0.001, P = 0.03, and P = 0.03). The mean number of anti-vascular endothelial growth factor injections was 2.8 ± 2.0 over 12 months. Complete resolution of myopic CNV was noted in 22 eyes (55.0%) after initial first injection, and no additional treatment was required in 12 eyes (30%).
Better baseline BCVA, lacquer crack extension to the fovea, and peripapillary atrophy were negative prognostic factors of visual acuity improvement, and there was quite a promising result of anti-vascular endothelial growth factor treatment in patients with myopic CNV.
[Show abstract][Hide abstract] ABSTRACT: To evaluate the association between improvement of photoreceptor integrity and visual acuity (VA) after anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (AMD).
Retrospective, cross-sectional study.
Eighty-seven eyes of 84 patients who were newly diagnosed with neovascular AMD and treated with anti-VEGF injections were reviewed retrospectively. Using spectral-domain optical coherence tomography, the status of the inner segment/outer segment photoreceptor junction (IS/OS) was graded and classified into 3 groups at baseline and 1 and 2 months after 3 monthly injections. The proportion of the improved IS/OS line after treatment was analyzed and correlated with VA.
The number of eyes in the IS/OS+ group, representing disrupted IS/OS line less than 200 μm, was increased from 9 (10%) at baseline to 33 (38%) at 1 month. There was a significant difference in the ratio of IS/OS+ group between baseline and 1 month (P < .001). Those in the IS/OS± group, showing focal disrupted IS/OS line between 200 and 800 μm, decreased from 29 (33%) to 22 eyes (25%). Improvement of the IS/OS line at 1 month compared to baseline was noted in 43 eyes (49%) and correlated with better VA (P < .016). No increase of VA was observed in 44 eyes without definite improvement. There was no significant correlation between improvement of the IS/OS line and VA from 1 to 2 months.
Assessing the change of the photoreceptor integrity before and after treatment would be a useful indicator to predict initial response to treatment and visual prognosis in patients with neovascular AMD.
American Journal of Ophthalmology 04/2012; 154(1):164-173.e1. · 4.02 Impact Factor